UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2017
RITTER PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | | 001-37428 | | 26-3474527 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| 1880 Century Park East, Suite 1000 | | |
| Los Angeles, California | | 90067 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(310) 203-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01.Other Events.
On March 28, 2017, Ritter Pharmaceuticals, Inc. (the “Company”) issued a press release announcing topline findings from the Company’s Phase 2b/3 study designed to evaluate RP-G28 in subjects with lactose intolerance (the “Press Release”). A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
On March 29, 2017, the Company held a conference call and webcast to present the topline clinical trial results. A copy of the slides presented during that call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | | Description |
| | | |
| 99.1 | | Ritter Pharmaceuticals, Inc. press release dated March 28, 2017, entitled “Ritter Pharmaceuticals Announces its Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial” |
| | | |
| 99.2 | | Slide Presentation for Investor Conference Call and Webcast on March 29, 2017 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | RITTER PHARMACEUTICALS, INC. |
| | | |
| | By: | /s/ Michael D. Step |
| | Name: | Michael D. Step |
| | Title: | Chief Executive Officer |
Date: March 29, 2017
Exhibit Index
| Exhibit No. | | Description |
| | | |
| 99.1 | | Ritter Pharmaceuticals, Inc. press release dated March 28, 2017, entitled “Ritter Pharmaceuticals Announces its Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial” |
| | | |
| 99.2 | | Slide Presentation for Investor Conference Call and Webcast on March 29, 2017 |
